All G secures FDA "no questions" letter

Agronomics Limited

01 April 2026

 

Agronomics Limited
("Agronomics" or the "Company")

All G secures FDA "no questions" letter for precision fermented lactoferrin

DOUGLAS, ISLE OF MAN / 1 April 2026 - Agronomics (LSE: ANIC), a London-listed company focused on investment opportunities in the clean food sector, announces that its portfolio company, All G Co Holdings Pty Limited ("All G"), has completed the U.S. Food and Drug Administration's ("FDA") Generally Recognized as Safe ("GRAS") notification process for its precision fermented bovine lactoferrin.

All G has received a "no questions" letter from the FDA, confirming that the agency has no questions at this time regarding All G's conclusion that its recombinant lactoferrin is safe for use in food. This outcome enables the ingredient's commercialisation in the United States, a significant market for functional ingredients and dietary supplements.

All G is an Australian biotechnology company developing next-generation milk proteins using precision fermentation. Its lactoferrin product, marketed as LFX™, is intended for use in functional food and beverage applications, dietary supplements and early life nutrition. The company states that the ingredient is produced through a controlled fermentation process and purified to defined specifications, with analytical testing indicating purity levels in excess of 99.5%.

Agronomics considers this regulatory clearance an important step for All G, supporting near-term commercial activity in the United States and providing a broad reference point for precision fermented functional proteins. The development is consistent with Agronomics' strategy of investing in scalable, high-value ingredients with defined commercial pathways.

Jim Mellon, Executive Chair of Agronomics, said: "FDA clearance for All G's precision fermented lactoferrin is an important milestone for the company and for the broader precision fermentation sector. Regulatory validation of this kind reduces uncertainty around commercial deployment and supports the transition from technical development to revenue generation. All G operates in a category characterised by strong demand, constrained traditional supply and attractive pricing dynamics. We believe this outcome positions the company to establish itself as a supplier of high-value functional proteins to global nutrition markets."

Lactoferrin has an established history of use in the United States, including in infant formula, dietary supplements and functional foods. All G has indicated that the GRAS determination is expected to support its broader regulatory strategy, including future applications in early life nutrition and expansion into additional jurisdictions.

Agronomics first invested in All G in August 2022 and has subscribed a total of £8.9 million to date, which, subject to audit, is currently carried at approximately £7.4 million. This position represents around 5% of Agronomics' most recently reported Net Asset Value of £139.9 million as at 31 December 2025. Agronomics invested an additional AU$ 3 million in All G in January 2026 through a convertible loan. The Company will provide further updates as All G progresses toward commercial launch.

About All G

All G is an Australian biotechnology company developing next-generation human and bovine milk proteins using precision fermentation technology. The company is advancing a portfolio of recombinant proteins, including lactoferrin, to enable nutrition formulations with improved functionality, consistency and scalability.

About Agronomics

Agronomics is a leading London-listed company focused on investment opportunities in the clean food sector. The Company has built a diversified portfolio spanning cellular agriculture, precision fermentation and enabling biomanufacturing technologies.

A full list of Agronomics' portfolio companies is available at www.agronomics.im.

For further information, please contact:

Agronomics Limited	Beaumont Cornish Limited	Canaccord Genuity Limited	Cavendish Capital Markets Limited	33Seconds Limited
The Company	Nomad	Joint Broker	Joint Broker	Public Relations
Jim Mellon Denham Eke	Roland Cornish James Biddle	Andrew Potts Harry Pardoe	Giles Balleny Michael Johnson	Jack Ferris Amber Carr
[phone] [e-mail]	[phone]	[phone]	[phone]	[phone] [e-mail]

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media-only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

END